Hematology-Oncology – Page 2

Elevated Von Willebrand Factor and Factor VIII Show Promise as Biomarkers for Diagnosis and Monitoring of Chronic Graft-Versus-Host Disease

By MedXY 05/27/2026

In a prospective cohort, VWF and FVIII were significantly elevated in chronic graft-versus-host disease, tracked with disease activity, and showed moderate diagnostic performance for early cGvHD.

Hematology-Oncology news Oncology

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY 05/27/2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Self-Reinforcing IL-1β Signaling Accelerates TCF3::HLF-Positive B-ALL Development and Relapse

By MedXY 05/27/2026

Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.

Diabetes & Endocrinology Hematology-Oncology news

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome

By MedXY 05/26/2026

Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.

Hematology-Oncology news Otorhinolaryngology

Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma

By MedXY 05/25/2026

P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.

Hematology-Oncology news Oncology

Frontline Allogeneic Transplantation Outperforms Pretransplant IPSS-M Downstaging in Myelodysplastic Neoplasms

By MedXY 05/21/2026

In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mortality.

AI Hematology-Oncology news

Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others

By MedXY 05/21/2026

A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.

Hematology-Oncology news

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML

By MedXY 05/18/2026

Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.

Hematology-Oncology news

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement

By MedXY 05/18/2026

Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.

Hematology-Oncology news

Evolution of Tumor Subclones and T-Cell Dynamics Underlie Variable Ibrutinib Responses in Waldenström Macroglobulinemia

By MedXY 05/18/2026

Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.

Hematology-Oncology news Pediatrics

Poverty Exposure in Standard-Risk Pediatric B-ALL Is Linked to Steroid-Resistance Programs and an Immunologically Suppressed Leukemia Microenvironment

By MedXY 05/14/2026

Single-cell RNA sequencing suggests that childhood poverty exposure is associated with steroid-resistance signatures in leukemic blasts and adverse immune remodeling at diagnosis in standard-risk B-ALL.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma

By MedXY 05/14/2026

In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.

Hematology-Oncology news Oncology

Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia

By MedXY 05/11/2026

A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.

Dermatology Hematology-Oncology news

A New CTCL-Specific Quality-of-Life Tool Shows Strong Early Validity Signals in Cutaneous T-Cell Lymphoma

By MedXY 05/11/2026

A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.

Hematology-Oncology news

CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies

By MedXY 05/11/2026

Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.

Hematology-Oncology news Oncology

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

By MedXY 05/11/2026

A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.

Hematology-Oncology news Oncology

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY 05/09/2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast cancer.

Critical Care Hematology-Oncology news

急性白血病危重成人患者的時間趨勢和預後因素：個體參與者數據薈萃分析

By MedXY 05/09/2026

這項涵蓋19國55個ICU的2003名患者研究發現，急性白血病危重患者總體ICU死亡率為45%，需機械通氣者達66%。年齡>65歲、AML診斷、化療期間入院等因素顯著增加死亡風險，但隨時間推移生存率有所改善。

Clinical Updates Hematology-Oncology news

Optimizing Busulfan Precision Dosing: A Synthesis of Real-World Pharmacokinetics, Obesity, and Drug Interactions

By MedXY 05/09/2026

This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.

Hematology-Oncology news Public Health

Ethnicity Influences Relapse-Free Survival in Immune-Mediated Thrombotic Thrombocytopenic Purpura

By MedXY 05/09/2026

A French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.